Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

"NEOadjuvant Plus Adjuvant Therapy With Combination or Sequence of Vemurafenib, cobImetinib, and atezolizuMab in Patients With High-risk, Surgically Resectable BRAF Mutated and Wild-type Melanoma"

NCT04722575 is registered in ClinicalTrials.gov with Fondazione Melanoma Onlus as lead sponsor.

NCT NCT04722575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04722575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
"NEOadjuvant Plus Adjuvant Therapy With Combination or Sequence of Vemurafenib, cobImetinib, and atezolizuMab in Patients With High-risk, Surgically Resectable BRAF Mutated and Wild-type Melanoma"
Lead sponsor
Fondazione Melanoma Onlus
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 3, 2020
Completion date
June 30, 2027
Enrollment
95 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma